Chemically Defined, High-Density Insect Cell-Based Expression System for Scalable AAV Vector Production.

Area of Science:

• Biotechnology
• Gene Therapy
• Viral Vector Production

Background:

• Adeno-associated virus (AAV) vectors are crucial for gene therapy, offering long-term in vivo transgene expression and low toxicity.
• Clinical applications of AAV are hindered by challenges in large-scale manufacturing.
• Baculovirus-based AAV production systems offer scalability and predictable biosafety.

Purpose of the Study:

• To improve baculovirus-based adeno-associated virus (AAV) vector production.
• To evaluate the ExpiSf Baculovirus Expression System for high-density cell culture and AAV manufacturing.
• To assess the yield and quality of AAV vectors produced using this enhanced system.

Main Methods:

• Utilized the ExpiSf Baculovirus Expression System with a chemically defined medium for suspension culture of ExpiSf9 cells.
• Infected ExpiSf9 cells with baculovirus to produce AAV vectors.
• Purified AAV vectors and quantified genome copies per mL of suspension culture.
• Administered AAV vectors to mice to assess transduction efficiency and biodistribution.

Main Results:

• Achieved up to 5 x 10^11 genome copies of highly purified AAV vectors per mL of suspension culture.
• Obtained up to a 19-fold higher yield compared to conventional Sf9 cell-based systems.
• Demonstrated comparable transduction efficiency and biodistributions in mice for AAV vectors produced in ExpiSf9 versus Sf9 cells.

Conclusions:

• The ExpiSf Baculovirus Expression System offers a simple and effective method to enhance AAV vector production.
• This system provides a significant increase in AAV yield, addressing a key manufacturing hurdle.
• The ExpiSf system supports facile and scalable AAV manufacturing suitable for preclinical and clinical gene therapy applications.